Eosinophilic esophagitis (EoE) is a chronic disorder of the esophagus characterized by an eosinophil-predominant inflammation and symptoms of esophageal dysfunction. Eosinophils can influence esophageal motility, leading to dysphagia worsening. The spectrum of esophageal motility in EoE is uncertain.
-
2022 (v1)PublicationUploaded on: February 14, 2024
-
2022 (v1)Publication
Gastro-esophageal reflux disease (GERD) occurs in about 25% of the general population. The complexity of the disease and the multiplicity of its clinical manifestations impair the availability of a singular diagnostic test. The majority of GERD patients do not have any endoscopically visible lesions, the so-called non erosive reflux disease...
Uploaded on: February 11, 2024 -
2020 (v1)Publication
: EoE incidence and prevalence have sharply increased in the last decade and management of these patients is changing rapidly. Standard regimens as elimination diet, proton pump inhibitors and topical swallowed steroids are not able to achieve remission in all patients. Moreover, loss of efficacy and safety concerns for long-term medical...
Uploaded on: April 14, 2023 -
2020 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Introduction: Gastroesophageal reflux disease (GERD) is one of the most prevalent conditions in Western Countries, normally presenting with heartburn and regurgitation. Extra-esophageal (EE) GERD manifestations, such as asthma, laryngitis, chronic cough and dental erosion, represent the most challenging aspects from diagnostic and therapeutic...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
The utilization of high-resolution manometry (HRM) has enhanced our understanding and assessment of esophageal motor disorders. Moreover, the combination of impedance technology with HRM (HRIM) has further improved our knowledge of esophageal physiology and the clinical evaluation of dysmotility, thanks to the addition of accurate measurement...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them. We prospectively analyzed data collected from 55...
Uploaded on: February 14, 2024 -
2021 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2021 (v1)PublicationAchalasia and Obstructive Motor Disorders Are Not Uncommon in Patients with Eosinophilic Esophagitis
An association has been reported between achalasia and eosinophilic esophagitis (EoE). We performed a retrospective study of high-resolution manometry (HRM) patterns in a large cohort of patients with EoE.
Uploaded on: April 14, 2023 -
2021 (v1)Publication
Background: Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their efficacy and safety in patients with IBD are still lacking. We aimed to compare the effectiveness and tolerability between adalimumab originator,...
Uploaded on: January 13, 2024 -
October 2020 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2021 (v1)Publication
Background The long-term course of ulcerative colitis after a severe attack is poorly understood. Second-line rescue therapy with cyclosporine or infliximab is effective for reducing short-term colectomy but the impact in the long-term is controversial.Objective The purpose of this study was to evaluate the long-term course of acute severe...
Uploaded on: February 4, 2024 -
2022 (v1)Publication
Irritable bowel syndrome with diarrhoea (IBS-D) and functional diarrhoea (FDr) are the two major functional bowel disorders characterized by diarrhoea. In spite of their high prevalence, IBS-D and FDr are associated with major uncertainties, especially regarding their optimal diagnostic work-up and management. A Delphi consensus was performed...
Uploaded on: January 31, 2024